United States Multiplex Assay Market Forecast 2024-2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $1,100	154 Pages	Inkwood Research	March, 2024	INKR18647243

Best Price Guarantee
Price	from $1,100
Length	154 Pages
Publisher	Inkwood Research
Published Date	March, 2024
SKU	INKR18647243

United States Multiplex Assay Market Forecast 2024-2032

KEY FINDINGS

The United States multiplex assay market is set to record a CAGR of 8.01% during the forecast period, 2024-2032. The market growth is attributed to advancements in technology and increased demand for efficient diagnostic solutions.

MARKET INSIGHTS

The distinct advantages of multiplex assays over singleplex and conventional assays are propelling the US market growth. Multiplex assays provide various benefits, including sample consumption reduction through miniaturization, enhanced operational efficiency, simplified operations, and decreased labor costs. These factors collectively contribute to the rising prevalence of Multiplex Assays in the United States.

Whereas the increasing need for healthcare systems to offer services at affordable rates is anticipated to impede the expansion of the Multiplex Assays Market. Nonetheless, the inherent value of multiplexed assay products and services in furnishing comprehensive and effective healthcare information indicates that the market holds promising long-term potential.

Nonetheless, the United States multiplex assay market is poised for continued growth, fueled by technological advancements, expanding applications across diverse sectors, and increasing adoption by healthcare professionals seeking more efficient diagnostic tools to improve patient care.

COMPETITIVE INSIGHTS

Some of the leading players in the market include Becton, Dickinson and Company (BD), Agilent Technologies Inc, Bio-Rad Laboratories Inc, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

1. Research Scope & Methodology: 1.1. Study Objectives; 1.2. Methodology; 1.3. Assumptions & Limitations
2. Executive Summary: 2.1. Market Size & Estimates; 2.2. Country Snapshot; Country Analysis; 2.3. Scope Of Study; 2.4. Crisis Scenario Analysis; 2.5. Major Market Findings; 2.5.1. Software And Services Sector Emerges As The Rapidly Expanding Product & Service Segment; 2.5.2. Protein-based Multiplex Assay Is The Highest Revenue-generating Type; 2.5.3. Research & Development Applications Dominate Market Share; 2.5.4. Multiplex Pcr Technology Demonstrates Faster Growth; 2.5.5. Pharmaceutical And Biotechnology Companies Are Major Users Of Multiplex Assays
3. Market Dynamics: 3.1. Key Drivers; 3.1.1. Escalating Incidence Of Chronic Diseases; 3.1.2. Growing Preference For Multiplex Assays Over Conventional Approaches; 3.1.3. Increasing Acceptance Of Personalized Medicine; 3.2. Key Restraints; 3.2.1. Overcoming The Difficulty Of Establishing Sufficient Assay Range; 3.2.2. Challenges Associated With Cross-reactivity And Assay Interference; 3.2.3. Shortage Of Skilled Professionals
4. Key Analytics: 4.1. Key Market Trends; 4.1.1. Rising Drug Discovery Endeavors; 4.1.2. Progress In Assay Platform Technology; 4.1.3. Rapid Expansion Of Companion Diagnostics; 4.2. Pestle Analysis; 4.2.1. Political; 4.2.2. Economical; 4.2.3. Social; 4.2.4. Technological; 4.2.5. Legal; 4.2.6. Environmental; 4.3. Porter’s Five Forces Analysis; 4.3.1. Buyers Power; 4.3.2. Suppliers Power; 4.3.3. Substitution; 4.3.4. New Entrants; 4.3.5. Industry Rivalry; 4.4. Market Concentration Analysis; 4.5. Key Buying Criteria; 4.5.1. Coverage Of Analytes; 4.5.2. Rapidity; 4.5.3. Ability To Multiplex; 4.5.4. User-friendliness; 4.5.5. Automation Potential; 4.6. Value Chain Analysis; 4.6.1. Research And Development (R&D); 4.6.2. Manufacturing And Production; 4.6.3. Distribution And Supply Chain; 4.6.4. Clinical Application And Data Analysis; 4.6.5. Market Research And Commercialization
5. Market By Product And Service: 5.1. Reagents And Consumables; 5.1.1. Market Forecast Figure; 5.1.2. Segment Analysis; 5.2. Instruments And Accessories; 5.2.1. Market Forecast Figure; 5.2.2. Segment Analysis; 5.3. Software And Services; 5.3.1. Market Forecast Figure; 5.3.2. Segment Analysis
6. Market By Type: 6.1. Protein-based Multiplex Assay; 6.1.1. Market Forecast Figure; 6.1.2. Segment Analysis; 6.2. Nucleic Acid-based Multiplex Assay; 6.2.1. Market Forecast Figure; 6.2.2. Segment Analysis; 6.3. Other Types; 6.3.1. Market Forecast Figure; 6.3.2. Segment Analysis
7. Market By Application: 7.1. Research And Development; 7.1.1. Market Forecast Figure; 7.1.2. Segment Analysis; 7.2. Clinical Diagnostics; 7.2.1. Market Forecast Figure; 7.2.2. Segment Analysis; 7.3. Companion Diagnostics; 7.3.1. Market Forecast Figure; 7.3.2. Segment Analysis
8. Market By Technology: 8.1. Multiplex Protein Microarray; 8.1.1. Market Forecast Figure; 8.1.2. Segment Analysis; 8.2. Multiplex Pcr; 8.2.1. Market Forecast Figure; 8.2.2. Segment Analysis; 8.3. Other Technologies; 8.3.1. Market Forecast Figure; 8.3.2. Segment Analysis
9. Market By End-user: 9.1. Pharmaceutical & Biotechnology Companies; 9.1.1. Market Forecast Figure; 9.1.2. Segment Analysis; 9.2. Research Institutes; 9.2.1. Market Forecast Figure; 9.2.2. Segment Analysis; 9.3. Clinical Laboratories; 9.3.1. Market Forecast Figure; 9.3.2. Segment Analysis; 9.4. Hospitals; 9.4.1. Market Forecast Figure; 9.4.2. Segment Analysis
10. Competitive Landscape: 10.1. Key Strategic Developments; 10.1.1. Mergers & Acquisitions; 10.1.2. Product Launches & Developments; 10.1.3. Partnerships & Agreements; 10.1.4. Business Expansions & Divestitures; 10.2. Company Profiles; 10.2.1. Agilent Technologies Inc; 10.2.1.1. Company Overview; 10.2.1.2. Product Portfolio; 10.2.1.3. Strengths & Challenges; 10.2.2. Becton, Dickinson And Company (Bd); 10.2.2.1. Company Overview; 10.2.2.2. Product Portfolio; 10.2.2.3. Strengths & Challenges; 10.2.3. Bio-rad Laboratories Inc; 10.2.3.1. Company Overview; 10.2.3.2. Product Portfolio; 10.2.3.3. Strengths & Challenges; 10.2.4. Bio-techne Corporation; 10.2.4.1. Company Overview; 10.2.4.2. Product Portfolio; 10.2.5. Illumina Inc; 10.2.5.1. Company Overview; 10.2.5.2. Product Portfolio; 10.2.5.3. Strengths & Challenges; 10.2.6. Merck Millipore; 10.2.6.1. Company Overview; 10.2.6.2. Product Portfolio; 10.2.7. Thermo Fisher Scientific Inc; 10.2.7.1. Company Overview; 10.2.7.2. Product Portfolio; 10.2.7.3. Strengths & Challenges